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Demographic properties of OSA patients
Group 1
FQRS (+)
n=89
Group 2
FQRS (-)
n=64 P-value
Age (years) 51.869.31 47.2210.60 0.018
Gender (male/female) 58/ 27 22/14 0.53
Hypertension, n(%) 30 (65.2%) 16 (34.8%) 0.41
Diabetes Mellitus, n(%) 10(58.8%) 7(41.2%) 0.26
Body mass index (kg/m2) 33.8916 31.525.9 0.39
Apnea-hypopnea index
(events/hour)
37.7928.14 25.5121.14 0.004
Lowest nocturnal oxygen
saturation (%)
66.9127.56 78.8621.14 0.025
Length of time SpO2<90%
(minute)
41.6759.6 16.240 0.021
ACE inhibitor n(%) 21(58.3%) 15(41.7%) 0.08
b-blocker n(%) 10(62.5%) 6(37.5%) 0.55
ACE: angiotensin converting enzymeEchocardiographic properties of OSA patients
FQRS (+)
n=89
FQRS (-)
n=64 P value
LVEDD (mm) 48.26 3.7 44.73.17 0<0.001
LVESD (mm) 29.62.8 26.722.67 0<0.001
EF (%) 67.93.64 69.564.23 0.031
IVS (mm) 10.70 1.06 10.31 1 0.066
PW (mm) 10.60 1.06 10  1 0.003
LV MASSINDEX (kg/m2) 92.4218.76 77.5213.43 0<0.001
LA (mm) 38.67 3.17 35.8 3 0<0.001
E (m/s) 66.313.02 76 15.33 0.007
A (m/s) 75.1715.9 7115.7 0.317
E/A ratio 0.930.32 1.120.34 0.033
Em (mm/sn) 0.10.2 0.70.3 0.109
Am (mm/sn) 0.110.2 0.100.3 0.051
Sm (mm/sn) 0.090.02 0.522.3 0.112
E/Em ratio 71.8 7.022.7 0.955
RVD (mm) 24.755.4 22.054.53 0.047
RAD (mm) 34.35.64 32.24.69 0.436
Tapse (mm) 23.662.7 23.842.56 0.792
Tei index 0.69 0.24 0.42 0.12 <0.001
A: late diastolic mitral inﬂow; A’: late diastolic mitral annular velocity; E: early diastolic mitral
inﬂow; E’: early diastolic mitral annular velocity; EF: ejection fraction; IVS: interventricular
septum; LA: left atrium; LV: left ventricle; LVEDD: left ventricular end-diastolic diameter;
LVESD: left ventricular end-systolic diameter; EF: Ejection Fraction; PW: posterior wall; S: peak
systolic mitral annular velocity; TAPSE: tricuspid annular plane systolic excursion. RAD: right
atrial minör dimension,RVD: right ventricular mid cavity diameter
Univariate correlation analysis and multivariable regression analysis for FQRS
beta P OR 95% CI P
Age 0.208 0.022 0.903 (0.823-0.991) 0.344
Apnea-hypopnea
index
0.332 <0.001 0.329 (0.073-1.483) 0.070
Lowest nocturnal
oxygen saturation
-0.374 <0.001 0.970 (0.946-0.995) 0.018
Length of time
SpO2<90%
0.339 <0.001 1.009 (0.991-1.027) 0.344
Tei index 0.526 <0.001 1.112 (1.056-1.170) <0.001
Lv mass õndex 0.400 <0.001 1.087 (1.029-1.148) 0.003
EF -0.161 0.080 0.937 (0.796-1.104) 0.437
Lv mass õndex: Left Ventricular Mass Index, EF: Ejection Fraction
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Ivabradine Terminated Incessant Right and Left Atrial Tachycardia
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Introduction: Ivabradine, a nonselective blocker of HCN channel isoforms, as a heart
rate decreasing agent, has been validated in the therapy of coronary artery disease,
heart failure and inappropriate sinus tachycardia3. On the other hand, overexpression
of HCN channels in atrial and ventricular myocytes urged investigators to consider the
presumptive arrhythmogenic effects. However, this agent has not been validated as an
antiarrhythmic agent so far.
Case Presentation: The ﬁrst case, a 58-year old male who had coronary artery bypass
surgery 3 months ago was admitted to our hospital with palpitation of whom ECG
diagnosis was atrial ﬁbrillation. Cardioversion was attempted. However, sinus rhythm
was not restored and incessant atrial tachycardia ensued with a rate of 127 bpm
(Fig.1a). Patient was offered Ivabradine. With his approval, ivabradine was given 7.5
mg bid and on the third day changed to 22.5 mg daily. The next day tachycardia
terminated and sinusal rhythm of 60 bpm prevailed (Fig 1b). However, because of
visual side effects ivabradine was withheld and the tachycardia of 117 bpm resumed
on the very same day (Fig 1c). The day after, the rate increased to 133 bpm (Fig.1d).
So was the patient taken to EPS and single RF application ablated right atrial
tachycardia originating from coronary sinus ostium (Fig.1e).
The second case was a 60-year old male to whom metoprolol, diltiazem and sotalol
had been given to relieve symptom of palpitation for last two months. ECG diagnosis
was repetitive incessant atrial tachycardia with varying degree atrioventricular block
(Fig.2a). In the same manner ivabradine 2x7.5 mg was started. On the next day, the
atrial rhythm was slower and sinus beats were intervening (Fig.2b). Two days later
ivabradine was increased to 22.5 mg daily and the day after, slow atrial rhythm ensued
and no sinus beats were detected (Fig. 2c).
The third case, a 67-year old female with no apparent cardiac disorder, had
incessant left atrial tachycardia after failed cryoablation of pulmonary veins (PV)
(Fig.3a). Flecainide was changed to ivabradine 2x 7.5 mg and two days later the
rhythm was restored to sinus (Fig 3b).
The fourth case, a 59-year old female with hypertension and left ventricular
hypertrophy, had paroxysmal atrial ﬁbrillation while she was on amiodarone and
metoprolol (Fig.4a). The day after amiodarone was replaced with ivabradine, the
rhythm was sinusal bradycardia. Following the cessation of metoprolol the rate
increased from 45 to 61 bpm (Fig.4b-4c).
Discussion: Probably our cases are the ﬁrst to prove that ivabradine, at starting doses
which were shown as well tolerated before, can terminate sustained atrial tachyar-
rhythmias resistant to potent antiarrhythmic agents.
In conclusion, ivabradine may be a choice in drug therapy of atrial tachyarrhyth-
mias. Being effective not only on left atrial but on right atrial tachycardia as well, it
may have efﬁcacy to prevent atrial ﬁbrillation relapses.LS C47
Table 1. Baseline demographic and clinical features by vasovagal syncope
types
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Males (%) 47,1 42,9 100,0 42,6 0,515
Age (years) 35,6+/-
15,3
35,5+/-
14,5
42,1+/-
20,6
33,1+/-
14,7
0,122
BMI (kg/m2) 24,0+/-4,9 23,6+/-4,3 24,4+/-5,4 22,5+/-4,6 0,006
weight (kg) 67,0+/-
14,0
66,7+/-
13,7
64,2+/-
13,4
64,1+/-
14,1
0,048
Smoker (%) 30,4 27,4 28,0 27,1 0,535
Trauma (%) 19,6 19,2 36,0 20,8 0,093
Baseline HR
(n/min)
74,9+/-
12,2
74,3+/-
12,4
76,4+/-
14,4
76,1+/-
11,5
0,738
Baseline SBP
(mmHg)
123,8+/-
13,8
123,7+/-
15,3
128,7+/-
16,1
121,2+/-
11,9
0,184
Baseline DBP
(mmHg)
73,3+/-9,9 72,6+/-
10,3
73,3+/-9,9 72,6+/-9,5 0,510
Symptomatic
HR* (n/min)
72,1+/-
39,3
43,7+/-
14,9
25,0 104,9+/-
32,4
0,000
Symptomatic
SBP*(mmHg)
70,9+/-
19,6
66,4+/-
21,7
110,0 75,6+/-
15,9
0,002
Symptomatic
DBP*(mmHg)
41,1+/-
14,5
38,8+/-
15,9
60,0 43,5+/-
12,2
0,061
CAD (%) 3,9 2,7 12,0 2,1 0,167
DM (%) 4,4 2,7 12,0 2,1 0,204
HT(%) 13,7 12,3 20,0 10,4 0,670
Presence of
prodromes (%)
82,8 93,2 80,0 81,3 72,4
Dizziness (%) 29,4 32,9 40,0 27,1 0,175
Blurred
vision(%)
21,6 24,7 12,0 25,0 0,175
Palpitation(%) 16,7 20,5 8,0 16,7 0,175
Sweating (%) 7,4 6,8 8,0 4,2 0,175
Nausea (%) 5,9 5,5 4,0 8,3 0,175
Test duration
(minute)
45,3+/-8,9 40,5+/-8,5 42,2+/-6,9 44,0+/-6,9 0,180
Mean values+/-SD #median (minimum-maximum) HR:Heart Rate SBP:systolic blood pressure
DBP:diastolic blood pressure DM: Diabetes HT: hypertension CAD: coronary artery disease
*available for 146 symptomatic patients.
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Clinical Features, Prodrome Types and Vasovagal Syncope Types in Passive and
Nitrate Potentiated Head Up Tilt Test
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Burcu Demirkan1, Ayse Colak1
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Background and Aim: Head-up tilt test (HUTT) is frequently used for patients with
unexplained syncope. So far, no study conducted in Turkey has evaluated the rela-
tionship between clinical features of patients with unexplained syncope and HUTT
results. The aim of this study was to assess characteristics of the patients during active
and passive stages of HUTT.
Methods: Patients with a history of unexplained syncope underwent HUTT. Initially,
patients had 10 minutes supine rest and then were tilted up to 70 degrees for
20 minutes. That phase was called "passive phase". Patients who had syncope during
passive phase were grouped under the heading of “passive (+)”. At the end of the
passive phase, in case of no syncope, 5mg sublingual isosorbiddinitrate was applied to
potentiate the HUTT. That phase was called "active phase". Patients who had syncope
during active phase were grouped under the heading of “active (+)”. If no symptoms
occurred during the active phase, the test was terminated after waiting for 25 minutes.
The test was considered (+) if syncope occurred. The syncope types were classiﬁed
according to Vasovagal Syncope International Study (VASIS) classiﬁcation: mixed
type, cardioinhibitory (CI) type and vasodepressor (VD) type.
Results: We enrolled 205 patients to the study. The mean age was 35.615.3 and the
mean body mass index (BMI) was 24.04.9. Seventy-one percent of the patients wereC48 JACC VHUTT positive: 135 patients (65.9%) were active (+), 11 patients (5.4%) were passive
(+). Of all patients, 4.4% had diabetes, 13.7% had hypertension, 3.9% had coronary
artery disease, 19.6% had trauma and 30.4% were current smokers. About eighty-three
percent of patients had prodromal symptoms such as dizziness (29.4%), blurred vision
(21.6%), palpitation (16.7%), sweating (7.4%) and nausea (5.9%). Mean test duration
was 45.38.9 minutes (min 10-max 55 minutes). Smokers had more syncope episodes
in previous 6 months (p:0.029). According to VASIS classiﬁcation, 52.7 % of the
patients had mixed type, 46.6% had VD type and 0.7% had CI type syncope. There
was no gender difference between different VVS types (p:0.241). Patients who had (-)
HUTT had higher BMI (p¼0.011). Active (+) patients had more history of trauma
during a syncopal episode (p:0.040) and had lower diastolic blood pressure (p:0.024).
Total HUTT duration was shorter in passive (+) patients (p<0.001). There was no
signiﬁcant difference regarding presence of cardiovascular risk factors and prodromal
symptoms between active (+) and passive (+) patients.
Conclusion: In our study, clinical characteristics were not associated with syncope
type and HUTT outcome. Patients whose tests were (-), had higher BMI. Active (+)
patients had more history of trauma and had lower symptomatic DBP while total
HUTT duration was shorter in passive (+) patients.
Keywords: cardioinhibitor, head up tilt test, nitrate, prodrome, vasodepressor,
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